Luye Pharma Group Ltd banner

Luye Pharma Group Ltd
HKEX:2186

Watchlist Manager
Luye Pharma Group Ltd Logo
Luye Pharma Group Ltd
HKEX:2186
Watchlist
Price: 2.51 HKD 3.72% Market Closed
Market Cap: HK$10B

Multiples-Based Value

The Multiples-Based Value of one Luye Pharma Group Ltd stock under the Base Case scenario is hidden HKD. Compared to the current market price of 2.51 HKD, Luye Pharma Group Ltd is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Luye Pharma Group Ltd Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Luye Pharma Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Luye Pharma Group Ltd
HKEX:2186
9.4B HKD 1.3 20.9 4.2 6.8
US
Eli Lilly and Co
NYSE:LLY
869B USD 13.3 42.1 28.4 30.3
US
Johnson & Johnson
NYSE:JNJ
588.6B USD 6.2 22 15.2 18.7
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.4 11.5 13
UK
AstraZeneca PLC
LSE:AZN
227.8B GBP 5.3 30.4 16.8 23.7
US
Merck & Co Inc
NYSE:MRK
297.7B USD 4.6 16.3 10.1 12.3
CH
Novartis AG
SIX:NOVN
231.9B CHF 5.4 21.7 13.4 17.2
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
US
Pfizer Inc
NYSE:PFE
159.7B USD 2.6 20.5 7.8 10.4
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.4 10.2 7.6 8.9
US
Bristol-Myers Squibb Co
NYSE:BMY
122.1B USD 2.5 17.3 7.3 9
P/E Multiple
Earnings Growth PEG
CN
Luye Pharma Group Ltd
HKEX:2186
Average P/E: 22.1
20.9
34%
0.6
US
Eli Lilly and Co
NYSE:LLY
42.1
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.4
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
30.4
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.3
14%
1.2
CH
Novartis AG
SIX:NOVN
21.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.5
22%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
1%
10.2
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Luye Pharma Group Ltd
HKEX:2186
Average EV/EBITDA: 45.3
4.2
9%
0.5
US
Eli Lilly and Co
NYSE:LLY
28.4
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.8
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
CH
Novartis AG
SIX:NOVN
13.4
5%
2.7
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
-9%
N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Luye Pharma Group Ltd
HKEX:2186
Average EV/EBIT: 99.2
6.8
14%
0.5
US
Eli Lilly and Co
NYSE:LLY
30.3
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.7
6%
3.1
CH
Roche Holding AG
SIX:ROG
13
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
23.7
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2
CH
Novartis AG
SIX:NOVN
17.2
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
-4%
N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
2%
4.5
US
Bristol-Myers Squibb Co
NYSE:BMY
9
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett